Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
Rhea-AI Summary
Dyne Therapeutics (Nasdaq: DYN) will announce topline results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, DYNE-251) on December 8, 2025.
The company will host an investor conference call and webcast at 8:00 a.m. ET on that day; a press release will be issued before the event. The webcast and an accompanying slide presentation will be available on Dyne’s Events & Presentations page, and a replay will be accessible for 90 days after the presentation.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus 1 Up
DYN fell 2.27% while close peers were mixed: SRPT -2.73%, IMCR -3.22%, PROK -8.95%, MESO +1.77%, HRMY +4.08%. Moves do not point to a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Earnings and pipeline | Positive | -2.9% | Q3 2025 results, cash runway and timelines for DYNE-251 and DYNE-101. |
| Nov 03 | Investor conferences | Neutral | +6.8% | Announcements of multiple healthcare conference presentations and webcasts. |
| Oct 06 | Clinical data update | Positive | -3.1% | One-year ACHIEVE Phase 1/2 data for DYNE-101 showing functional gains. |
| Oct 02 | Board appointment | Positive | +4.1% | Appointment of experienced executive Brian Posner to the board. |
| Sep 29 | Regulatory designation | Positive | -5.9% | Japanese Orphan Drug designation for DYNE-251 and recap of DELIVER data. |
Clinically and regulatory positive news has often been followed by negative next-day moves, while management and conference updates have seen more supportive price action.
Over the last few months, Dyne reported Q3 2025 results with cash of $791.9M and runway into Q3 2027, plus expectations for DELIVER REC topline in Dec 2025, yet the stock fell 2.88%. Positive ACHIEVE one-year data and Japanese Orphan Drug designation for DYNE-251 also coincided with declines of 3.14% and 5.93%. In contrast, a board appointment on Oct 2 and investor conference announcements in early November saw gains. Today’s announcement of a REC topline review call fits into this pattern of major clinical and regulatory milestones drawing focused investor attention.
Market Pulse Summary
This announcement sets expectations for topline results from the DELIVER registrational expansion cohort of DYNE‑251, with data and an investor call scheduled for December 8, 2025 at 8:00 a.m. ET. Historically, Dyne’s clinical and conference‑linked updates have produced sizable price swings, both positive and negative, so this event may be a key focus point. Investors tracking the story may watch how the REC findings relate to earlier DELIVER data and the company’s broader neuromuscular pipeline plans.
Key Terms
webcast technical
AI-generated analysis. Not financial advice.
WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) on December 8, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.
Investor Conference Call and Webcast
The webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne’s website, and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available. To view the webcast and replay, please visit https://investors.dyne-tx.com/news-and-events/events-and-presentations.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
FAQ
When will Dyne Therapeutics (DYN) announce topline REC results from the DELIVER trial?
What time is the Dyne Therapeutics (DYN) investor webcast for DELIVER REC results?
Where can investors watch the Dyne (DYN) DELIVER REC results webcast and access slides?
Will Dyne (DYN) provide a press release before the DELIVER webcast?
How long will the replay of Dyne’s (DYN) DELIVER presentation be available?
What drug and trial does Dyne (DYN) plan to report REC topline results for on December 8, 2025?
